Silexion Therapeutics Corp Stock Price, News & Analysis

Silexion Therapeutics (NASDAQ: SLXN) has completed a crucial preclinical study evaluating its RNAi therapeutic candidate SIL204 across multiple cancer types. The study assessed SIL204's potential in treating colorectal cancer (GP2D), lung cancer (A427), and pancreatic cancer (Panc-1) cell lines with KRAS mutations.

The company plans to announce comprehensive results in the coming days. This expansion beyond pancreatic cancer targets a significant market opportunity, as KRAS mutations occur in approximately 90% of pancreatic cancers, 45% of colorectal cancers, and 35% of non-small-cell lung cancers. The combined treatment market for these indications exceeds $30 billion annually.

Silexion Therapeutics (NASDAQ: SLXN) reported Q1 2025 financial results and business updates, highlighting significant progress in their RNAi therapy development for KRAS-driven cancers. Their lead candidate SIL204 demonstrated remarkable efficacy in preclinical studies, showing ~70-80% reduction in tumor cells and decreased metastatic spread in orthotopic models. The company strengthened its financial position by raising over $9 million in gross funds during Q1. Cash position improved to $6.2 million as of March 31, 2025, up from $1.2 million at end-2024. Q1 operating expenses were $1.7 million, with net loss at $1.7 million. The company announced a strategic collaboration with Catalent for SIL204's formulation development and unveiled plans for clinical trials in H1 2026.

Silexion Therapeutics (NASDAQ: SLXN) has announced a strategic collaboration with Catalent for the formulation development and clinical manufacturing of SIL204, their next-generation siRNA candidate. The partnership will utilize Catalent's Limoges facility in France to optimize both systemic and intratumoral delivery formulations of SIL204.

The collaboration follows Silexion's recent preclinical breakthrough showing SIL204's efficacy in reducing primary tumor growth and metastatic spread in pancreatic cancer models. SIL204 targets multiple KRAS mutations (G12D, G12V, G12R, Q61H, and G13D) important in pancreatic, colorectal, and lung cancers.

The company aims to initiate human clinical trials in H1 2026, with plans for regulatory submissions to the Israel Ministry of Health in H2 2025 and to the European Union in H1 2026. Throughout 2025, Silexion will conduct additional toxicology and pharmacodynamic studies as part of their comprehensive development strategy.

Silexion Therapeutics (NASDAQ: SLXN) has announced an expanded development plan for SIL204, its next-generation siRNA candidate targeting KRAS-driven pancreatic cancer. The new strategy combines both intratumoral and systemic administration approaches to target primary tumors and metastases.

The expansion follows promising preclinical data showing significant tumor growth inhibition in orthotopic models through systemic administration. Recent studies demonstrated SIL204's ability to reduce metastases to secondary organs, with pharmacokinetic data showing sustained drug levels for approximately two months after a single subcutaneous dose.

The development roadmap includes:

• Additional toxicology and pharmacodynamic studies throughout 2025
• Planned regulatory submissions to Israel Ministry of Health in H2 2025
• European Union submission targeted for H1 2026
• Human trials initiation planned for H1 2026

Silexion Therapeutics has completed an expanded development plan for SIL204, its next-generation siRNA candidate targeting KRAS-driven cancers. The plan will be presented at the NeauxCancer 2025 Conference in New Orleans from March 27th-29th, 2025.

The strategic plan, building on recent promising preclinical data, aims to maximize SIL-204's potential across multiple delivery approaches. The company's presentation is scheduled for March 28th at 1:00pm during the conference's Innovation track, where they will present their strategic vision alongside recently reported preclinical findings.

The clinical-stage biotechnology company, specializing in RNA interference (RNAi) therapies, will focus particularly on pancreatic cancer in their comprehensive approach to targeting KRAS-driven cancers.

Silexion Therapeutics (NASDAQ: SLXN) reported its financial results for 2024, marking a transformative year highlighted by its Nasdaq listing and advancement in RNAi therapies for KRAS-driven cancers. The company's second-generation candidate SIL204 showed promising results in reducing tumor burden and metastatic spread in pancreatic cancer models.

Key financial highlights include:

• Cash position of $1.2M as of December 31, 2024 (down from $4.6M in 2023)
• Total operating expenses increased to $12.6M (from $4.7M in 2023)
• Net loss of $16.5M (compared to $5.1M in 2023)
• Recent funding raised approximately $9.1M gross proceeds ($7.9M net)

Clinical highlights include a 56% objective response rate in Phase 2 LODER™ trial for pancreatic cancer patients with KRAS mutations, and plans to initiate SIL204 Phase 2/3 trials by first half of 2026.

Silexion Therapeutics (NASDAQ: SLXN) has reported breakthrough preclinical data for its SIL204 therapeutic candidate, showing promising results in treating KRAS-driven cancers, particularly pancreatic cancer. The orthotopic model studies demonstrated:

• ~70% reduction in tumor cell bioluminescence in AsPC-1 model (KRAS G12D mutation)
• Dose-dependent tumor cell reductions in Panc-1 model
• Up to 80% overall tumor cell reduction in BxPC-3 model

Notably, this marks the first systematic validation of a therapy's ability to suppress metastatic spread through systemic administration. The precision medicine market is projected to grow from $102 billion in 2024 to $470 billion by 2034. Maxim Group maintains a 'Buy' rating with a $9 price target, representing a ~600% premium over current price. The company is preparing to unveil an expanded development plan for SIL204, potentially exploring broader clinical applications.

Silexion Therapeutics (NASDAQ: SLXN) announced positive initial data from orthotopic pancreatic cancer models for their SIL204 treatment. The study demonstrated that subcutaneously administered SIL204 effectively reduces both primary tumor growth and metastatic spread.

Key findings include:

• ~70% reduction in tumor cell numbers in AsPC-1 (KRAS G12D mutation) by day 28
• In Panc-1 (KRAS G12D), tumor cells decreased 12% while control group increased >100% by day 14
• ~80% reduction in BxPC-3 (KRAS wild-type) by day 28
• Significant reduction in metastatic spread across liver, intestine, spleen and stomach in Panc-1 and BxPC-3 models

The results validate SIL204's efficacy in a more clinically relevant setting, where human pancreatic tumor cells are implanted directly into the pancreas. The company is finalizing an updated development strategy based on these findings.

Silexion Therapeutics (NASDAQ: SLXN) is approaching a important milestone with upcoming orthotopic pancreatic cancer model data for its SIL-204 therapy. The study evaluates the treatment's effectiveness in reducing primary tumor growth and inhibiting metastatic spread in pancreatic cancer models.

Previous studies have shown promising results, with SIL-204 demonstrating a 50% reduction in tumor growth and complete necrosis in half of treated tumors. The therapy has maintained therapeutic levels for over 56 days from a single dose. The RNAi-based approach targets multiple KRAS mutations (G12D, G12V, G12R, Q61H, and G13D), potentially offering broader therapeutic benefits than existing treatments.

The data readout, expected in March 2025, could validate systemic efficacy against metastatic disease for the first time. Maxim Group maintains a $9 price target and strong buy rating on SLXN, citing the company's clinical trajectory and RNAi platform validation.